WallStSmart

Evolent Health Inc (EVH)vsVeeva Systems Inc Class A (VEEV)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Veeva Systems Inc Class A generates 76% more annual revenue ($3.32B vs $1.89B). VEEV leads profitability with a 28.4% profit margin vs -26.3%. VEEV appears more attractively valued with a PEG of 0.88. VEEV earns a higher WallStSmart Score of 69/100 (B-).

EVH

Hold

44

out of 100

Grade: D

Growth: 5.3Profit: 2.0Value: 4.7Quality: 3.5
Piotroski: 4/9Altman Z: -0.57

VEEV

Strong Buy

69

out of 100

Grade: B-

Growth: 7.3Profit: 8.0Value: 7.3Quality: 9.0
Piotroski: 4/9Altman Z: 4.78
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for EVH.

VEEVUndervalued (+38.9%)

Margin of Safety

+38.9%

Fair Value

$289.59

Current Price

$207.91

$81.68 discount

UndervaluedFair: $289.59Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

EVH1 strengths · Avg: 10.0/10
Price/BookValuation
0.9x10/10

Reasonable price relative to book value

VEEV6 strengths · Avg: 9.2/10
Operating MarginProfitability
30.9%10/10

Strong operational efficiency at 30.9%

Debt/EquityHealth
0.0110/10

Conservative balance sheet, low leverage

Altman Z-ScoreHealth
4.7810/10

Safe zone — low bankruptcy risk

Profit MarginProfitability
28.4%9/10

Keeps 28 of every $100 in revenue as profit

PEG RatioValuation
0.888/10

Growing faster than its price suggests

Revenue GrowthGrowth
16.3%8/10

16.3% revenue growth

Areas to Watch

EVH4 concerns · Avg: 3.8/10
PEG RatioValuation
1.934/10

Expensive relative to growth rate

Revenue GrowthGrowth
2.6%4/10

2.6% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$474.67M3/10

Smaller company, higher risk/reward

VEEV1 concerns · Avg: 4.0/10
P/E RatioValuation
34.6x4/10

Premium valuation, high expectations priced in

Comparative Analysis Report

WallStSmart Research

Bull Case : EVH

The strongest argument for EVH centers on Price/Book.

Bull Case : VEEV

The strongest argument for VEEV centers on Operating Margin, Debt/Equity, Altman Z-Score. Profitability is solid with margins at 28.4% and operating margin at 30.9%. Revenue growth of 16.3% demonstrates continued momentum.

Bear Case : EVH

The primary concerns for EVH are PEG Ratio, Revenue Growth, EPS Growth. Debt-to-equity of 2.49 is elevated, increasing financial risk.

Bear Case : VEEV

The primary concerns for VEEV are P/E Ratio.

Key Dynamics to Monitor

EVH profiles as a turnaround stock while VEEV is a growth play — different risk/reward profiles.

VEEV carries more volatility with a beta of 0.94 — expect wider price swings.

VEEV is growing revenue faster at 16.3% — sustainability is the question.

VEEV generates stronger free cash flow (1.1B), providing more financial flexibility.

Bottom Line

VEEV scores higher overall (69/100 vs 44/100), backed by strong 28.4% margins and 16.3% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Evolent Health Inc

HEALTHCARE · HEALTH INFORMATION SERVICES · USA

Evolent Health, Inc., through its subsidiary, Evolent Health LLC, provides healthcare delivery and payment solutions in the United States. The company is headquartered in Arlington, Virginia.

Visit Website →

Veeva Systems Inc Class A

HEALTHCARE · HEALTH INFORMATION SERVICES · USA

Veeva Systems Inc. provides cloud-based software for the life sciences industry in North America, Europe, Asia Pacific, the Middle East, Africa, and Latin America. The company is headquartered in Pleasanton, California.

Visit Website →

Want to dig deeper into these stocks?